Log in

REMUS Remus Pharmaceuticals Ltd. NSE · India

Remus Pharmaceuticals (REMUS) news

Remus Pharmaceuticals Ltd. is a public biotech or pharmaceutical company listed on NSE under the ticker REMUS, recorded under India. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Remus Pharmaceuticals news

We have not published a story on Remus Pharmaceuticals yet. When there is news, it will appear here.

Questions about Remus Pharmaceuticals

What is the ticker symbol of Remus Pharmaceuticals?

Remus Pharmaceuticals Ltd. trades under the ticker REMUS on NSE.

Where is Remus Pharmaceuticals listed?

Remus Pharmaceuticals Ltd. is listed on NSE.

Which country or territory is Remus Pharmaceuticals listed under?

Our directory records Remus Pharmaceuticals Ltd. under India.

What does Remus Pharmaceuticals do?

Our directory classifies Remus Pharmaceuticals Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Remus Pharmaceuticals?

The ISIN recorded for Remus Pharmaceuticals Ltd. is INE0O5T01011.

Does aibio.space cover Remus Pharmaceuticals?

aibio.space lists Remus Pharmaceuticals Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Remus Pharmaceuticals?

Companies in our directory listed in the same country and business area as Remus Pharmaceuticals: Sakar Healthcare, Kopran, Corona Remedies, Lasa Supergenerics, Panchsheel Organics, Concord Drugs.

Investor discussion: Remus Pharmaceuticals

Members talk about Remus Pharmaceuticals (REMUS). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NSE:REMUS on TradingView.

Listing details

Remus Pharmaceuticals Ltd. is a public biotech or pharmaceutical company listed on NSE under the ticker REMUS, recorded under India. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Remus Pharmaceuticals Ltd.
Ticker
REMUS
Listing
NSE
Country or territory
India
Business scope
Pharmaceuticals: Major
ISIN
INE0O5T01011
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.